The Experts below are selected from a list of 141216 Experts worldwide ranked by ideXlab platform
James Sullivan - One of the best experts on this subject based on the ideXlab platform.
-
oncotype dx Colon Cancer assay for prediction of recurrence risk in patients with stage ii and iii Colon Cancer a review of the evidence
Surgical Oncology-oxford, 2015Co-Authors: Rudolph B Rustin, James SullivanAbstract:Abstract Advances in molecular biology have enabled identification of tumor biomarkers that allow for individualized risk assessment for patients with Cancer. Molecular predictors of clinical outcome can help inform discussion regarding the role of adjuvant chemotherapy in patients with resected Colon Cancer, such as those with stage II Colon Cancer in which the benefit of adjuvant therapy is controversial or those with stage III Colon Cancer who may have a lower risk of recurrence and less absolute benefit from oxaliplatin therapy. This article summarizes the data surrounding the development, validation, and clinical and economic utility of the Oncotype DX ® Colon Cancer assay, a multigene expression assay validated to independently predict recurrence risk in patients with stage II and III Colon Cancer beyond traditional factors.
Miroslaw Mazurczak - One of the best experts on this subject based on the ideXlab platform.
-
prospective multicenter study of the impact of oncotype dx Colon Cancer assay results on treatment recommendations in stage ii Colon Cancer patients
Oncologist, 2014Co-Authors: Geetika Srivastava, Lindsay A Renfro, Robert J Behrens, Margarita Lopatin, Calvin Chao, Gamini S Soori, Shaker R Dakhil, Rex B Mowat, Philip J Kuebler, Miroslaw MazurczakAbstract:Purpose.The Oncotype DX Colon Cancer assay is a clinically validated predictor of recurrence risk in stage II Colon Cancer patients. This prospective study evaluated the impact of recurrence score (RS) results on physician recommendations regarding adjuvant chemotherapy in T3, mismatch repairproficient (MMR-P) stage II Colon Cancer patients. Patients and Methods. Stage IIA Colon Cancer patients were enrolled in 17 centers. Patient tumor specimens were assessed by the RS test (quantitative reverse transcriptionpolymerase chain reaction) and mismatch repair (immunohistochemistry). For each patient, the physician’ sr ecommended postoperative treatment plan of observation, fluoropyrimidine monotherapy, or combination therapy with oxaliplatin wasrecorded before and afterthe RSand mismatch repair results were provided. Results. Of221enrolledpatients,141patientshadT3MMRP tumors and were eligible for the primary analysis. Treatment recommendations changed for 63 (45%; 95% confidence interval: 36%–53%) of these 141 T3 MMR-P patients, with intensity decreasing for 47 (33%) and increasing for 16 (11%). Recommendations for chemotherapydecreasedfrom73patients(52%)to42(30%),following review of RS results by physician and patient. Increased treatment intensity was more often observed at higher RS values,anddecreasedintensitywasobservedatlowervalues (p 5 .011). Conclusion. Compared with traditional clinicopathological assessment,incorporationoftheRSresultintoclinicaldecision making was associated with treatment recommendation changes for 45% of T3 MMR-P stage II Colon Cancer patients in this prospective multicenter study. Use of the RS assay may leadtooverallreductioninadjuvantchemotherapyuseinthis subgroup of stage II Colon Cancer patients. The Oncologist 2014;19:492–497
Rudolph B Rustin - One of the best experts on this subject based on the ideXlab platform.
-
oncotype dx Colon Cancer assay for prediction of recurrence risk in patients with stage ii and iii Colon Cancer a review of the evidence
Surgical Oncology-oxford, 2015Co-Authors: Rudolph B Rustin, James SullivanAbstract:Abstract Advances in molecular biology have enabled identification of tumor biomarkers that allow for individualized risk assessment for patients with Cancer. Molecular predictors of clinical outcome can help inform discussion regarding the role of adjuvant chemotherapy in patients with resected Colon Cancer, such as those with stage II Colon Cancer in which the benefit of adjuvant therapy is controversial or those with stage III Colon Cancer who may have a lower risk of recurrence and less absolute benefit from oxaliplatin therapy. This article summarizes the data surrounding the development, validation, and clinical and economic utility of the Oncotype DX ® Colon Cancer assay, a multigene expression assay validated to independently predict recurrence risk in patients with stage II and III Colon Cancer beyond traditional factors.
Ulrike Stein - One of the best experts on this subject based on the ideXlab platform.
-
Colon Cancer metastasis macc1 and met as metastatic pacemakers
The International Journal of Biochemistry & Cell Biology, 2009Co-Authors: Franziska Arlt, Ulrike SteinAbstract:Colon Cancer is still the second most frequent malignancy in the Western world. Despite major efforts in diagnosis and treatment it is one of the leading causes of Cancer related deaths. The metastatic dissemination of primary tumors is directly linked to patient's survival and accounts for about 90% of all Colon Cancer deaths. Current clinical predictions on whether Colon Cancer will metastasize are mainly defined by histopathological staging, describing the tumor spread within a surgical specimen. This review focuses on the need for molecule-based staging as essential prerequisite for individualized diagnosis, prognosis and therapy. Molecular determinants for progression and metastasis of Colon Cancer are discussed. Moreover, a newly identified molecule playing a decisive role in Colon Cancer metastasis is highlighted: MACC1. MACC1 acts as a key regulator of the metastasis-inducing HGF/Met pathway, predicts the risk for metastasis in early Cancer stages, and represents a novel target to attack metastasis.
Ruggero De Maria - One of the best experts on this subject based on the ideXlab platform.
-
Identification and expansion of human Colon-Cancer-initiating cells
Nature, 2007Co-Authors: Lucia Ricci-vitiani, Dario G. Lombardi, Mauro Biffoni, Matilde Todaro, Emanuela Pilozzi, Cesare Peschle, Ruggero De MariaAbstract:Colon carcinoma is the second most common cause of death from Cancer. The isolation and characterization of tumorigenic Colon Cancer cells may help to devise novel diagnostic and therapeutic procedures. Although there is increasing evidence that a rare population of undifferentiated cells is responsible for tumour formation and maintenance, this has not been explored for colorectal Cancer. Here, we show that tumorigenic cells in Colon Cancer are included in the high-density CD133+ population, which accounts for about 2.5% of the tumour cells. Subcutaneous injection of Colon Cancer CD133+ cells readily reproduced the original tumour in immunodeficient mice, whereas CD133- cells did not form tumours. Such tumours were serially transplanted for several generations, in each of which we observed progressively faster tumour growth without significant phenotypic alterations. Unlike CD133- cells, CD133+ Colon Cancer cells grew exponentially for more than one year in vitro as undifferentiated tumour spheres in serum-free medium, maintaining the ability to engraft and reproduce the same morphological and antigenic pattern of the original tumour. We conclude that colorectal Cancer is created and propagated by a small number of undifferentiated tumorigenic CD133+ cells, which should therefore be the target of future therapies.